Funding for this research was provided by:
Canadian Institutes of Health Research (376801)
Received: 18 June 2020
Accepted: 15 September 2020
First Online: 25 September 2020
Ethics approval and consent to participate
: The methods, design and procedures for this study were approved by the Bruyère Research Ethics Board (protocol # M16–17-009) and are in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study. Following each interview, the patient was asked for verbal permission to approach relevant caregivers and healthcare providers (e.g., primary care providers, GDH pharmacist and physicians) for their consent to participate in subsequent interviews about the patient’s prescribing cascade(s). If the patient agreed, caregivers and healthcare providers involved in their care were invited to participate in similar semi-structured interviews (in-person or by telephone).
: Not applicable.
: Dr. Farrell and Dr. McCarthy received compensation for travel and accommodation (BF) and registration (BF, LM) to give a presentation on the topic of prescribing cascades at the Ontario Pharmacists’ Association and Canadian Pharmacists Association annual meeting in June 2019. Dr. Farrell also received compensation for travel to a research team meeting in October 2019.